MMRV vaccine
| Combination of | |
|---|---|
| Measles vaccine | Vaccine |
| Mumps vaccine | Vaccine |
| Rubella vaccine | Vaccine |
| Varicella vaccine | Vaccine |
| Clinical data | |
| Trade names | Proquad, Priorix Tetra |
| Other names | Measles, Mumps, Rubella, and Varicella Virus Vaccine Live |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous, intramuscular |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| (what is this?) (verify) | |
The MMRV vaccine is a combination vaccine against measles, mumps, rubella (German measles), and varicella (chickenpox). It contains the combined measles vaccine, mumps vaccine, rubella vaccine, and varicella vaccine into a single injection. The MMRV vaccine has similar immunogenicity and overall safety profiles to the MMR vaccine administered with or without the varicella vaccine. The MMRV vaccine is typically given to children between one and two years of age.
Several companies supply MMRV vaccines. Proquad is marketed by Merck and was approved in 2005, for use in the United States for children aged twelve months of age through twelve years of age. Stand-alone virus measles, mumps, rubella, and varicella vaccines had been previously licensed in 1963, 1967, 1969, and 1995, respectively. An MMRV vaccine called Priorix Tetra by GlaxoSmithKline is available in some of the member states of the European Union.